In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture
Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks
Australian Regenerative Medicine company Mesoblast recently suffered a significant financial setback in the ongoing development of MPC-150-IM, their experimental Phase III treatment for chronic heart failure, with their key US
Texcell, a French provider of biosafety contract services, recently acquired German company Vivo Science GmbH, a GLP/GMP compliant contract research test facility specialising in toxicology, immunology & virology in vivo
Thermo Fisher Scientific have further cemented their reputation as a serial acquirer with the purchase of FEI Company for approximately $4.2B in cash. Oregon-based FEI Company are world leaders in
Last week German multinational Bayer put forward an all-cash $62B bid for American AgTech giant Monsanto, further emphasizing the unprecedented period of consolidation that the global AgriBusiness market is currently
Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo
A recent mixed securities shelf registration filing by Thermo Fisher Scientific has prompted speculation from industry insiders and investors, with prominent advisors predicting further acquisitions for the company throughout 2016
China made its boldest overseas takeover move yet this week, announcing that state-owned company ChemChina has submitted a $43 billion bid for Swiss seeds and pesticides group Syngenta with the
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic
Thermo Fisher Scientific have signed a definitive agreement to acquire Alfa Aesar, a leading global manufacturer of research chemicals, for £256 million (approximately $405 million USD) in cash. Alfa Aesar’s
The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.
Sigma-Aldrich’s acquisition by Merck has been conditionally cleared by the European Commission, and has received full clearance from the Chinese Ministry of Commerce. Merck and Sigma have already cleared from
